Endra life sciences inc. (NDRA)
CashFlow / TTM
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Cash Flows from Operating Activities
Net loss

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

80

79

77

72

68

63

60

61

61

62

63

64

64

0

0

0

Common stock, options and warrants issued for services

1,399

1,328

1,277

1,290

1,367

1,462

1,446

1,352

1,002

631

449

181

230

0

0

0

Additional warrants issued during exchange

-

-

-

-

-

-

-

-

-

-

-

-

-5

0

0

0

Interest on discount of convertible debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Imputed interest on promissory notes

-

-

-

-

-

-

-

-

1

5

5

4

3

0

0

0

Amortization of debt discount

-

-

-

-

-

-

-

-

711

0

0

0

-

-

-

-

Changes in operating assets and liabilities:
Increase in accounts receivable

0

-12

-11

-11

-6

12

11

11

6

0

0

0

-

-

-

-

Increase in prepaid expenses

-28

-121

-75

66

77

226

314

-37

67

101

4

76

0

0

0

0

Increase in inventory

53

127

82

115

155

155

145

205

151

11

13

-62

-58

0

0

0

Increase in deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Decrease in other asset

106

345

347

255

259

8

7

1

3

3

1

7

2

0

0

0

Increase in accounts payable and accrued liabilities

760

135

615

-24

126

756

589

351

528

170

20

157

198

0

0

0

Net cash used in operating activities

-8,588

-8,583

-7,569

-7,791

-7,702

-7,175

-6,253

-5,516

-3,300

-2,471

-1,924

-1,498

-1,315

0

0

0

Cash Flows from Investing Activities:
Purchases of fixed assets

43

5

105

105

100

0

0

0

-

-

-

-

-

-

-

-

Net cash used in investing activities

-43

-5

-105

-105

-100

-100

0

-7

-7

-7

-7

0

0

0

0

0

Cash Flows from Financing Activities
Proceeds from notes payable

-

-

-

-

-

-

-

-

-

-

-

-

50

0

0

0

Proceeds from senior secured convertible promissory notes, net of fees

-

-

-

-

-

-

-

-

225

93

280

1,479

1,254

0

0

0

Proceeds from issuance of common stock

-

-

-

-

-

-

-

-

-

-

-

-

5

0

0

0

Net cash provided by financing activities

-

-

-

-

-

-

-

-

8,765

8,765

8,952

1,611

1,441

0

0

0

Net decrease (increase) in cash

-297

1,638

61

775

869

-6,340

-5,318

3,016

5,456

6,901

7,019

113

125

0

0

0

Supplemental disclosures:
Interest paid

0

40

40

40

40

0

0

0

0

0

0

0

-

-

-

-

Interest Paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Income tax paid

-

0

0

0

-

0

0

0

-

0

0

0

0

0

0

0

Supplemental disclosures of non-cash Items:
Discount on convertible notes

-

-

-

-

-

-

-

-

225

225

225

225

0

0

0

0

Common shares to be issued for accrued salaries - related parties

-

-

-

-

-

-

-

-

-

-

-

-

60

0

0

0